MARKET

JNCE

JNCE

Jounce
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.29
-0.42
-4.80%
Opening 12:19 10/30 EDT
OPEN
8.66
PREV CLOSE
8.71
HIGH
8.68
LOW
8.21
VOLUME
113.43K
TURNOVER
--
52 WEEK HIGH
11.72
52 WEEK LOW
2.850
MARKET CAP
283.70M
P/E (TTM)
13.46
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
If You Had Bought Jounce Therapeutics (NASDAQ:JNCE) Shares A Year Ago You'd Have Earned 147% Returns
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...
Simply Wall St. · 4d ago
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers
Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%.
Seekingalpha · 09/16 15:00
Jounce Therapeutics (JNCE) Investor Presentation - Slideshow
The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with this event.
Seekingalpha · 09/11 21:44
Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash
Jounce therapeutics is a differentiated player in the hot immuno-oncology sector.JNCE stock has not been fairly priced after its newly struck partnership with Gilead Sciences, making it a compelling buy for the short term.JNCE's drug discovery engine continues to impress, potentially making it an equally compelling pick for the longer term.
Seekingalpha · 09/11 18:06
September Markets Struggle To Provide Consistent Trades
Continuing a trend that I’ve been experiencing for weeks now in my trading, momentum in the market remains muted. At the same time, promising charts persist in breaking down and taking out whatever gains I have been able to post.
Benzinga · 09/04 19:38
Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in September
GlobeNewswire · 09/02 20:01
Gilead Inks Deal With Jounce to License an Oncology Candidate
Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.
Zacks · 09/02 13:25
Mid-Afternoon Market Update: Dow Surges 100 Points; ScanSource Shares Slide Following Q4 Earnings
Toward the end of trading Tuesday, the Dow traded up 0.37% to 28534.69 while the NASDAQ rose 1.13% to 11908.25. The S&P also rose, gaining 0.43% to 3515.27.
Benzinga · 09/01 18:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JNCE. Analyze the recent business situations of Jounce through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JNCE stock price target is 14.30 with a high estimate of 28.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 127
Institutional Holdings: 29.17M
% Owned: 85.25%
Shares Outstanding: 34.21M
TypeInstitutionsShares
Increased
28
1.10M
New
24
84.37K
Decreased
31
1.49M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.95%
Pharmaceuticals & Medical Research
-1.00%
Key Executives
Chairman/Independent Director
Perry Karsen
President/Chief Executive Officer/Director
Richard Murray
Chief Financial Officer/Treasurer
Kimberlee Drapkin
Other
Hugh Cole
Other
Elizabeth Trehu
Independent Director
Luis Diaz
Secretary
Jacqui Sandell
Independent Director
Barbara Duncan
Independent Director
J. Duncan Higgons
Independent Director
Robert Iannone
Independent Director
Robert Kamen
Independent Director
Cary Pfeffer
Independent Director
Robert Tepper
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About JNCE
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Jounce Therapeutics Inc stock information, including NASDAQ:JNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JNCE stock methods without spending real money on the virtual paper trading platform.